Dry Eye News and Research

RSS
Dry eye is one of the most common complaints seen by eye doctors, accounting for nearly one fourth of all office visits. Caused by insufficient tear production or excessive tear evaporation, dry eye can be a mild, episodic feeling of discomfort associated with certain circumstances, such as exposure to dry, hot or windy environments; however, it can also be a chronic medical condition that, if left untreated, may lead to increased risk of infection or visual impairment.
Adverse environmental changes present potential health hazards to eyes

Adverse environmental changes present potential health hazards to eyes

BioLight announces first sale of IOPtiMate system in Portugal

BioLight announces first sale of IOPtiMate system in Portugal

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

BioLight signs joint financing agreement with two Asia-based venture capital firms

BioLight signs joint financing agreement with two Asia-based venture capital firms

Allergan signs licensing agreement with Mimetogen to develop, commercialize tavilermide for treatment of dry eye disease

Allergan signs licensing agreement with Mimetogen to develop, commercialize tavilermide for treatment of dry eye disease

Allergan completes acquisition of AqueSys

Allergan completes acquisition of AqueSys

Matricellular proteins may be key therapeutic targets for common ocular disorders

Matricellular proteins may be key therapeutic targets for common ocular disorders

UK’s GPs, optometrists confirm link between smoking and loss of vision

UK’s GPs, optometrists confirm link between smoking and loss of vision

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

BioLight Life Sciences Investments reports operational and financial results for Q2 2015

BioLight Life Sciences Investments reports operational and financial results for Q2 2015

Researchers report significant progress in management of patients with dry eyes

Researchers report significant progress in management of patients with dry eyes

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Laser eye surgery: a glimpse into the future - An interview with Professor Dan Reinstein

Laser eye surgery: a glimpse into the future - An interview with Professor Dan Reinstein

Shire acquires Foresight Biotherapeutics for $300 million

Shire acquires Foresight Biotherapeutics for $300 million

Allergan enters into agreement to acquire Oculeve

Allergan enters into agreement to acquire Oculeve

Redwood Pharma signs licensing agreement with Broda Technologies for hydrogel drug delivery technology

Redwood Pharma signs licensing agreement with Broda Technologies for hydrogel drug delivery technology

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight expands relationship with Ora to develop TeaRx multi-parameter diagnostic test for DES

BioLight expands relationship with Ora to develop TeaRx multi-parameter diagnostic test for DES

BioLight Life Sciences reports operational and financial results for Q1 2015

BioLight Life Sciences reports operational and financial results for Q1 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC